The AJMC® Leukemia & Lymphoma compendium is a comprehensive resource for clinical news and expert insights for the blood cancers and their treatments.
Palliative Care Shortcomings for Patients With Hematologic Malignancies Addressed in New Review
A recent review explored current palliative care practices for patients with hematologic cancers compared with solid tumor cancers.
Study Shows Significant Disparities in Worldwide Rates of Non-Hodgkin Lymphoma
Recent research used incidence and mortality data from the GLOBOCAN 2020 database to gain insight into worldwide patterns of non-Hodgkin lymphoma in 2020.
Challenging the “One-Size-Fits-All” Approach in Early MCL Treatment
Anita Kumar, MD, medical oncologist with Memorial Sloan Kettering Cancer Center, led a session at the 2022 Annual Meeting of the American Society of Clinical Oncology (ASCO), on New Directions in Mantle Cell Lymphoma.
Parental Age May Be Linked With Childhood Cancer Risk, but More Research Is Needed
A recent meta-analysis aimed to clarify the relationship between parental age and solid tumor pediatric cancers, but more studies are necessary to overcome the limitations of available research.
CD300 Molecules May Be Influential Immune Regulators, Therapy Targets in AML
Finding therapeutic targets for acute myeloid leukemia (AML) has proven challenging, but a set of immune-regulating molecules may hold promise as biomarkers and targets.
Novel Prognostic Biomarkers Indicate Prognosis in Acute Myeloid Leukemia
A novel prognostic model based on N 6-methyladenosine-associated long non-coding RNAs demonstrated accuracy in determining high- and low-risk disease, suggesting the associated risk value may have potential as a novel biomarker.
Study Identifies Novel PD-L2 Variant as Possible Predisposition Indicator in Lymphoma
Whole-exome sequencing of a family with early-onset cancers found a novel variant in programmed cell death 1 ligand 2 that could potentially indicate germline predisposition to lymphoma.
FDA Approves Tisa-Cel for Third Indication, R/R Follicular Lymphoma
Tisagenlecleucel (tisa-cel) was approved to treat adults with relapsed or refractory (R/R) follicular lymphoma. This is the third indication for the therapy since it became the first FDA-approved chimeric antigen receptor T-cell therapy in 2017.
AML and COVID-19: Chemotherapy Delay May Be the Best Approach
Patients being treated for acute myeloid leukemia (AML) who are diagnosed with COVID-19 may be best served by chemotherapy delay until after COVID-19 has run its course.
TIGIT May Hold Potential as a Marker of CAR T-Cell Exhaustion and Therapeutic Target in Non-Hodgkin Lymphoma
A recent study identified TIGIT as a marker of chimeric antigen receptor (CAR) T-cell exhaustion and found it to improve CAR T-cell therapy efficacy in preclinical models.
Adolescent, Young Adult Leukemia Survivors Face Higher Long-term Mortality Rates
While 5-year survival in adolescent and young adult leukemia has improved in recent decades, this patient population still faces increased long-term mortality compared with the general public.
Review Highlights Progress and Challenges in Treating HIV/AIDS-Associated Lymphoma
Significant progress has led to improved survival in patients with HIV/AIDS, but lymphoma remains a leading cause of morbidity and mortality in this patient population.
Case Series Suggests Venetoclax Plus Hypomethylating Agent Therapy Tolerable, Effective in Very Elderly AML Patients
Very elderly patients with acute myeloid leukemia have historically been limited to less intensive, less effective treatment regimens. A recent series of cases suggests age alone should not be a limiting factor for effective treatment.
Review Addresses Antifungal Prophylaxis in AML and Provides Guidance for Novel Agents
Patients with acute myeloid leukemia (AML) who have undergone intensive chemotherapy are at a very high risk for invasive fungal disease, and a changing treatment landscape warrants further research on drug-drug interactions and outcomes.
Hypomethylating Agents With Venetoclax Can Be Effective Bridge to Transplant in AML
Among a cohort of 88 patients with acute myeloid leukemia who received hypomethylating agents with venetoclax prior to allogeneic hematopoietic cell transplant, 85% had achieved morphologic complete response at 100 days.
Case Study Presents 3 Potential Novel Targets in Acute Myeloid Leukemia
Acute myeloid leukemia is a complicated heterogenous hematological cancer with a poor prognosis, but novel targets may lead to improved treatment and outcomes going forward.
AKR1C3 Expression May Hold Potential as a Biomarker, Clinical Target in T-ALL
Aldo-keto reductase 1C3 (AKR1C3) has been identified as a potential biomarker and target in several cancers, and a recent study found it to be a potential biomarker in T acute lymphoblastic leukemia/lymphoma (T-ALL).
Neurocognitive Changes After CAR T-Cell Therapy for NHL Similar to Other Cancers
With an increasing number of longer-term survivors treated with chimeric antigen receptor (CAR) T-cell therapy for non-Hodgkin lymphoma (NHL), more research is needed to confirm its effects on neurocognitive performance.
City of Hope’s Alvarnas: Payers Must Recognize Cancer Care Is Different
Joseph Alvarnas, MD, vice president of government affairs at City of Hope and chief clinical adviser of AccessHope in Duarte, California, spoke March 4 at the closing session of the Association for Community Cancer Centers (ACCC) Annual Meeting & Cancer Business Summit in Washington, DC.
Final Response Analysis of ALPINE Finds Zanubrutinib Superior to Ibrutinib in R/R CLL
Results of the phase 3 ALPINE trial provided found zanubrutinib was superior to ibrutinib in overall response rate.
Pretreatment PROs May Have Survival Implications in DLBCL, Finds Exploratory Study
The researchers found that the prognostic values for both overall and progression-free survival remained even after adjusting for the International Prognostic Index, a widely used prognostic model of outcomes for the disease.
Allogeneic CAR T-Cell Therapy Leads to Brief CR in Case Study of R/R B-Cell Lymphoblastic Leukemia
With further research, allogeneic CAR T-cell therapy may help overcome the cost and production time barriers currently associated with autologous CAR T-cell therapy.
Nearly One-Fourth of DLBCL Cases May Be Attributable to Obesity in Young Adulthood, Says Study
Across all measures, researchers found that body mass index in young adults had the strongest association with the risk of non-Hodgkin lymphoma (NHL), estimating that 23.3% of diffuse large B-cell lymphoma (DLBCL) cases and 11% of NHLs overall can be attributed to obesity.
Advances in LPL/WM Research Could Inform New Treatment Avenues
Investigators say it may soon be possible to design therapies better at staving off resistance among patients with lymphoplasmacytic lymphoma/Waldenström macroglobulinemia (LPL/WM), which is an incurable disease.
High CD47 Expression on HRS Cells Carries Poor Survival Implications in Classical HL
Retrospective study findings show that CD47 expression on Hodgkin and Reed–Sternberg (HRS) cells varied between patients who had classical Hodgkin lymphoma (HL) and was associated with poor outcomes.
BTK Inhibitor Zanubrutinib Leads to Modest Results Against Some DLBCL Malignancies
The authors of a new study say patients with certain mutations appear to respond to zanubrutinib, which had a favorable safety profile.
Axi-Cel Highly Effective as First-line Option in High-risk Large B-Cell Lymphoma
A Look at Current Trends and the Potential Future of Mantle Cell Lymphoma Therapy
A recent review examined currently approved treatments and those under investigation for mantle cell lymphoma.
Scientists Review New Research Strategies for Treating CLL
Approaches such as new types of monoclonal antibodies and chimeric antigen receptor natural killer cells could change how chronic lymphocytic leukemia is treated, according to a recent review article.
Review: Progress Made Toward More Precise Diagnosing of NK-LGL Leukemia
About 15% of cases of large granular lymphocytic leukemia involve natural killer cells.
2 Clarke Drive Cranbury, NJ 08512